Results 91 to 100 of about 931,718 (350)

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition [PDF]

, 2011
Overcoming de novo and acquired resistance to anticancer drugs that target signaling networks is a formidable challenge for drug design and effective cancer therapy.
Bown, James L., Faratian, Dana, Goltsov, Alexey, Goryanin, Igor, Harrison, David J., Langdon, Simon P.   +5 more
core   +4 more sources

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Multi-output prediction of dose–response curves enables drug repositioning and biomarker discovery

npj Precision Oncology
Drug response prediction is hampered by uncertainty in the measures of response and selection of doses. In this study, we propose a probabilistic multi-output model to simultaneously predict all dose–responses and uncover their biomarkers.
Juan-José Giraldo Gutierrez, Evelyn Lau, Subhashini Dharmapalan, Melody Parker, Yurui Chen, Mauricio A. Álvarez, Dennis Wang   +6 more
doaj   +1 more source

Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist

Heliyon, 2019
Objective: To identify an agonist of RXRα and RARα with reduced undesired profiles of all-trans retinoic acid for differentiation-inducing therapy of acute promyelocytic leukemia (APL), such as its susceptibility to P450 enzyme, induction of P450 enzyme,
Chie Koshiishi, Takanori Kanazawa, Eric Vangrevelinghe, Toshiyuki Honda, Shinji Hatakeyama   +4 more
doaj   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise. [PDF]

PLoS Computational Biology, 2014
In this work we investigate, by means of a computational stochastic model, how tumor cells with wild-type p53 gene respond to the drug Nutlin, an agent that interferes with the Mdm2-mediated p53 regulation.
Krzysztof Puszynski, Alberto Gandolfi, Alberto d'Onofrio   +2 more
doaj   +1 more source

PDX-derived organoids model in vivo drug response and secrete biomarkers

JCI Insight, 2020
Patient-derived organoid models are proving to be a powerful platform for both basic and translational studies. Here we conduct a methodical analysis of pancreatic ductal adenocarcinoma (PDAC) tumor organoid drug response in paired patient-derived ...
Ling Huang, B. Bockorny, Indranil Paul, Dipikaa Akshinthala, P. Frappart, Omar Gandarilla, Arindam Bose, Veronica Sanchez-Gonzalez, Emily E. Rouse, S. Lehoux, Nicole Pandell, C. Lim, J. Clohessy, Joseph M Grossman, Raul S Gonzalez, Sofia Perea Del Pino, G. Daaboul, M. Sawhney, S. Freedman, A. Kleger, R. Cummings, A. Emili, L. Muthuswamy, M. Hidalgo, S. Muthuswamy   +24 more
semanticscholar   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Practical considerations for optimal designs in clinical dose finding studies [PDF]

Determining an adequate dose level for a drug and, more broadly, characterizing its dose response relationship, are key objectives in the clinical development of any medicinal drug. If the dose is set too high, safety and tolerability problems are likely
Bretz, Frank, Dette, Holger, Pinheiro, José   +2 more
core  

Indometh acin-antihistamine combination for gastric ulceration control [PDF]

, 1980
An anti-inflammatory and analgesic composition containing indomethacin and an H2 histamine receptor antagonist in an amount sufficient to reduce gastric distress caused by the indomethacin was developed.
Brown, P. A., Vernikos, J.
core   +1 more source